Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

Valued at a market cap of $182.5 billion, Gilead Sciences, Inc. (GILD) is a Foster City, California–based biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. The company addresses significant unmet medical needs, with a strong leadership position in HIV treatments and a growing presence in oncology and inflammatory diseases through its expanding pipeline.

Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and GILD fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - general industry. The company is known for its...

Fundamentals

See More
  • Market Capitalization, $K 184,909,664
  • Shares Outstanding, K 1,241,421
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,023 M
  • EBITDA $ 12,790 M
  • 60-Month Beta 0.36
  • Price/Sales 6.28
  • Price/Cash Flow 13.73
  • Price/Book 7.89

Options Overview Details

View History
  • Implied Volatility 29.50% (+0.84%)
  • Historical Volatility 33.65%
  • IV Percentile 47%
  • IV Rank 28.26%
  • IV High 49.97% on 04/08/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 5) 3.92 (2.63%)
  • Put/Call Vol Ratio 0.52
  • Today's Volume 6,049
  • Volume Avg (30-Day) 10,661
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 157,573
  • Open Int (30-Day) 162,448
  • Expected Range 145.03 to 152.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.86
  • Number of Estimates 9
  • High Estimate 1.97
  • Low Estimate 1.73
  • Prior Year 1.81
  • Growth Rate Est. (year over year) +2.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
138.23 +7.76%
on 01/29/26
157.29 -5.30%
on 02/11/26
+7.98 (+5.66%)
since 01/27/26
3-Month
116.88 +27.44%
on 01/05/26
157.29 -5.30%
on 02/11/26
+21.44 (+16.81%)
since 11/26/25
52-Week
93.37 +59.53%
on 04/25/25
157.29 -5.30%
on 02/11/26
+36.96 (+33.00%)
since 02/27/25

Most Recent Stories

More News
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

ACLX : 113.79 (-0.08%)
XLV : 160.20 (+1.77%)
MRK : 123.82 (+3.79%)
GILD : 148.95 (+3.60%)
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

– Novel Investigational Combination Pairs Bictegravir, a Global Guideline-Recommended Integrase Strand Transfer Inhibitor with a High Barrier to Resistance with Lenacapavir, a First-in-Class...

GILD : 148.95 (+3.60%)
Is Amgen Stock Outperforming the Dow?

Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.

$DOWI : 48,977.92 (-1.05%)
GILD : 148.95 (+3.60%)
AMGN : 388.16 (+2.33%)
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

NFLX : 96.24 (+13.77%)
VRTX : 496.83 (+3.48%)
GILD : 148.95 (+3.60%)
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Arcellx , Inc....

ACLX : 113.79 (-0.08%)
GILD : 148.95 (+3.60%)
Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday,...

GILD : 148.95 (+3.60%)
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – ...

ACLX : 113.79 (-0.08%)
GILD : 148.95 (+3.60%)
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – ...

ACLX : 113.79 (-0.08%)
GILD : 148.95 (+3.60%)
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – ...

GILD : 148.95 (+3.60%)
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call

5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call

GILD : 148.95 (+3.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 158.14
2nd Resistance Point 154.07
1st Resistance Point 151.51
Last Price 148.95
1st Support Level 144.88
2nd Support Level 140.81
3rd Support Level 138.25

See More

52-Week High 157.29
Last Price 148.95
Fibonacci 61.8% 132.87
Fibonacci 50% 125.33
Fibonacci 38.2% 117.79
52-Week Low 93.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar